clinical trial · NCT05125068
Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy (IgAN)
IgA NephropathyIgANAT-1501
brief summary
This is a phase 2a, multicenter, open-label study designed to evaluate the safety and efficacy of AT-1501 in patients with biopsy proven IgAN and at least 0.75 g/24 hours of protein in their urine at the time of screening.
started
Mar 21, 2022
primary completion
Jul 31, 2023
completion
Jul 31, 2023
last updated
Mar 26, 2024
detailed description
Phase 2a, multicenter, open-label study designed to evaluate the safety and efficacy of AT-1501 in patients with biopsy proven IgAN and at least 0.75 g/24 hours of protein in their urine at the time of Screening. Up to 42 eligible patients will receive one of 2 doses of AT-1501. All patients are scheduled to receive AT-1501 by intravenous infusion every 3 weeks for approximately 2 years.
official title
A Phase 2a, Multicenter, Open-Label Study to Evaluate the Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol